the strength of the second hit seems to be a major component that differentiates APL from other types of AML. Following this line of thought, it may be suggested that in AML cells, apoptosis is induced by therapy, if chemotherapy significantly alters the inner cell balance between proliferation and differentiation signals (see figure) . Coexpression of 2 powerful drivers such as FLT3/ITD and NUP98/NDS1 creates a stable pathological balance that drives leukemia forward but is very difficult to disrupt by regular chemotherapies.
One conclusion from the study by Ostronoff et al is that AML patients coexpressing FLT3/ITD and NUP98/NDS1 may require alternative therapies. In vitro data suggest that FLT3 inhibitors may be an option. 6 Unfortunately, no clinical evidence favoring specific agents exist for patients presenting with both FLT3/ITD and NUP98/NSD1. In addition, because NUP98 can partner multiple other genes yielding oncogenic signals, it is worth exploring the clinical effect of other NUP98-related fusion transcripts. It might also be suggested that characterization of the interaction between proliferation and differentiation signals as a whole (may be by RNA expression patterns) may help progressing toward personalizing clinical decisions in AML. Leukemia patients presenting with a combination of a strong proliferation driver mutation and a dominant differentiation blocker are likely to require novel specific therapies. Inflammatory Langerhans cell differentiation as a factor induced in lesional skin from atopic dermatitis/eczema patients. 8 The critical novel point made by the current study was that TSLP synergizes with TGF-b1 for driving LC differentiation and that such a TSLP/TGF-b1-dependent LC precursor is included within the (potentially heterogenous) population of BDCA-1 1 blood DCs (see figure) . The absence/low expression of these inflammatory signals in the steady-state epidermis may indicate that the factors inducing LC differentiation during inflammation or in the steady-state epidermis differ. LCs were functionally implicated in tolerance induction, skin inflammation, and cancer; therefore, deciphering these LC-inducing signals is of substantial clinical interest. Apart from providing in vitro models for the study of LCs, these findings might lead to the identification of novel molecular targets for pharmacologic interference with skin diseases. Moreover, knowledge of these LC-instructive factors and the nature of blood precursors of LCs might allow for the improved generation of LCs for cell therapy applications and for gaining novel insights into the pathogenesis of monocyte/DC/LC-related neoplasms.
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